Related Experiment Video
Updated: May 10, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
Published on: October 23, 2020
Prognostic [68Ga]Ga-PSMA-11 PET Biomarkers for [177Lu]Lu-PSMA Radioligand Therapy in Metastatic Castrate-Resistant
Nicola Xin Yi Koh1, Wei Ming Chua2,3, Winnie Wing-Chuen Lam2,4
1Department of Internal Medicine, SingHealth, Singapore, Singapore.
Aims:
Gallium-68 (68Ga) prostate-specific membrane antigen (PSMA) ([68Ga]Ga-PSMA-11) directed PET/CT reflects PSMA expression at metastatic sites and can hence be a surrogate of lutetium-177 (177Lu) PSMA ([177Lu]Lu-PSMA) radiation delivery. This retrospective analysis aims to explore the association between quantitative baseline [68Ga]Ga-PSMA-11 PET imaging biomarkers and treatment outcomes in our Asian cohort.
Methods:
We included patients with progressive metastatic castrate-resistant prostate cancer (mCRPC) who received [177Lu]Lu-PSMA radioligand therapy at our institution. The association between baseline [68Ga]Ga-PSMA-11 PET parameters (SUVmax, SUVmean, total tumor volume [PSMA-TV], total lesion uptake [PSMA-TLU = PSMA-TV × SUVmean], and total lesion quotient [PSMA-TLQ = PSMA-TV / SUVmean]) and overall survival (OS), prostate specific antigen (PSA) progression free survival (PFS), PSA response, and toxicity were analyzed using univariate analysis. Optimal cut-points were also explored.
Results:
Between May 9, 2018 and October 7, 2024, 71 of 84 screened patients were eligible. The median whole-body SUVmean in our cohort was 8.04. Higher PSMA-TLQ and PSMA-TV (per 10-unit increment) were associated with shorter OS (HR 1.005; HR 1.005) and shorter PSA PFS (HR 1.005; HR 1.004). A higher PSMA-TLQ was also associated with poorer odds of PSA response (OR 0.994). Conversely, higher SUVmean was associated with longer PSA PFS (HR 0.911) and improved odds of PSA response (OR 1.34). Higher PSMA-TV (per 10-unit increment) and PSMA-TLU (per 100-unit increment) were associated with increased hematological toxicity (OR 1.008; OR 1.012).
Conclusion:
PSMA-TLQ and PSMA-TV were negative prognostic markers and SUVmean was a positive prognostic marker among Asian patients with mCRPC who received [177Lu]Lu-PSMA radioligand therapy.
More Related Videos
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
Related Concept Videos
Cancer Survival Analysis
Sensitivity, Specificity, and Predicted Value
Sensitivity is the...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Comparing the Survival Analysis of Two or More Groups
Kaplan-Meier Approach
Nursing Diagnosis
The nursing diagnosis focuses on evidence-based...